Close Menu

Bonnie Anderson

Jun 29, 2015

Castle Biosciences has appointed Bonnie Anderson to its Board of Directors. Anderson is the Co-founder, President, and CEO of molecular diagnostics firm Veracyte.

Prior to founding Veracyte, Anderson served as a consultant, drawing on her 18 years of experience at laboratory instrument firm Beckman Coulter. She is also a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences in Claremont, California. 

More Like This

Aug 22, 2019

Color: Jill Hagenkord

Jill Hagenkord is no longer chief medical officer of genetic testing firm Color, and has started a new consulting company, called MDisrupt. Hagenkord previously held executive positions at Invitae, 23andMe, and Complete Genomics. She co-founded MDisrupt with another 23andMe alum, Ruby Gadelrab, who is serving as CEO. The start-up describes itself as a "medical diligence company" that aims to help companies speed innovative products to market by "assessing a product's clinical and commercial viability in a healthcare setting."

Aug 22, 2019

Tempus: Joel Dudley

Joel Dudley has joined Tempus as senior vice president of research, in charge of all non-oncology R&D efforts for the company, which is in the midst of expanding from its original focus on cancer into cardiology and depression. Dudley previously was executive VP for precision health at Mount Sinai Health System and founding director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. 

Aug 21, 2019

Varian: Phil Febbo

Varian has appointed Phil Febbo to its board of directors. Febbo currently serves as chief medical officer at Illumina as well as on the board of the American College of Medical Genetics and Genomics Foundation. Prior to joining Illumina, he served as CMO at Genomic Health. Before working at Genomic Health, Febbo was a professor of medicine and urology at the University of California, San Francisco. 

Aug 21, 2019

PerkinElmer: Robert Friel, Prahlad Singh, Alexis Michas

After serving 12 years as CEO of PerkinElmer, Robert Friel will step down from that position as well as from his role as chairman of the board, effective Dec. 29, 2019. He will continue to serve as an advisor until March 1, 2020. The firm also announced that Prahlad Singh, current president and COO of PerkinElmer, will become CEO on Dec. 30, 2019, and he has been elected a director of the company, effective today. Prior to joining PerkinElmer in 2014, Singh was general manager of GE Healthcare's women's health business.

PerkinElmer also said that Alexis Michas, currently lead director, will serve as non-executive chairman of PerkinElmer's board, starting Dec. 30.

Aug 20, 2019

SEngine Precision Medicine: Tom Neary

SEngine Precision Medicine has appointed Tom Neary as its CFO. Before SEngine, Neary served as CFO at Space Venture Partners. Prior to working at Space Ventures Partners, he served as CFO at Spaceflight Industries. 

Aug 16, 2019

Yourgene: Jonathan Seaton

Yourgene has appointed Jonathan Seaton to its board of directors as a non-executive director. Seaton is currently serves as director at GenomOncology. Prior to that, he served as head of corporate and business development and government affairs at Becton Dickinson. Before Becton Dickinson, Seaton served as vice director, global business development at Roche Diagnostics from 2008-2015. Prior to Roche, he worked as a life sciences investment banker for Deutsche Bank. 

Aug 15, 2019

Aperiomics: C. Alexander Valencia

C. Alexander Valencia has joined Aperiomics as Chief Clinical Officer. He will oversee the microorganism sequencing firm's clinical test development, validations, regulatory affairs, and operations.

Prior to joining Aperiomics, Valencia served as molecular laboratory director at Cincinnati Children's Hospital Medical Center. He has experience at PerkinElmer Genomics. He holds a doctorate from Canada's Carleton University and the University of Ottawa and held post-doctoral positions in biochemistry and molecular biology at the University of North Carolina at Chapel Hill and in clinical molecular genetics at Emory University.

Aug 14, 2019

OraSure Technologies: James Datin

OraSure Technologies has appointed James Datin to its board. He will serve as a Class III director with his initial term expiring at the company's 2021 shareholders' meeting. He will serve on OraSure's audit and compensation committees. Datin is president and CEO of BioAgilytix, a global bioanalytical contract research organization which supports the development of therapeutic biologics. Prior to that, he was executive vice president and managing director at Safeguard Scientifics. 

Aug 13, 2019

Biodesix: Robert Georgantas III

Robert Georgantas III was appointed by Biodesix as its senior vice president of research and translational science. He was formerly director of immunology programs, genomics, and the Genetics Research Center of Excellence at AbbVie. Prior to that, he was a senior scientist in the department of translational sciences at Medimmune. 

Aug 09, 2019

NeoGenomics: Sharon Virag

NeoGenomics said in a document filed with the US Securities and Exchange Commission that CFO Sharon Virag has resigned from the company, effective immediately. NeoGenomics did not provide additional details. It will begin a search for her replacement "in due course," it said.

Aug 07, 2019

Progenity: Brian Kotzin

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

Aug 07, 2019

Oxford Nanopore Technologies: John Schoellerman

John Schoellerman has joined Oxford Nanopore Technologies as senior vice president of corporate development and investment. Previously, he was managing director and head of medtech at Lazard, and before that, he worked in healthcare investment banking at JP Morgan. Schoellerman holds a BA from Harvard University and an MBA from INSEAD.

Aug 06, 2019

Invitae: Randy Scott, Sean George

Invitae announced that Randy Scott will retire as executive chairman from its board of directors effective September 1. Invitae CEO Sean George will be the board's new chairman at that time. Scott served as CEO of Invitae between 2012 and 2017, after which George took over the reins. Scott said in a statement that he plans to continue to support the Invitae team as a private investor.

Aug 06, 2019

Serimmune: Noah Nasser, Bill Welch

Goleta, California-based Serimmune has appointed Noah Nasser as CEO and Bill Welch to its board of directors.

Prior to Seriummne, Nasser served as chief commercial officer at Human Longevity. Before working at Human Longevity, Nasser served as chief commercial officer at Counsyl. In addition, he held leadership positions at AltheaDx and Verinata Health. 

Welch is currently a venture partner at Illumina Ventures. Before joining Illumina Ventures, Welch served as CEO at Trovagene. Prior to Trovagene, Welch was president and CEO at Sequenom. Before working at Sequenom, Welch served as CCO at Monogram Biosciences. Prior to Monogram, Welch held progressive management positions at Abbot Laboratories. 

Aug 05, 2019

Foundation Medicine: Priti Hegde

Priti Hegde has been appointed as CSO of Foundation Medicine, a Roche company, effective August 5. She replaces Michael Doherty, who will be retiring in September. Previously, she held various posts at Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Prior to that, she was manager of disease and biomarker transcriptomics at GlaxoSmithKline. Hegde holds a PhD in biochemical pharmacology from SUNY Buffalo and a B. Pharmacy degree from Mumbai University in India.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.